-72%

est. 2Y upside i

HealthcareSeed

Rank

#301

Sector

Biotechnology, Drug Discovery

Est. Liquidity

~6Y

Data Quality

Data: Medium

Moonwalk Biosciences presents a high-risk, moderate-upside equity opportunity for a job seeker.

Last updated: March 10, 2026

Bull (20%)+400%

Moonwalk successfully advances its siRNA obesity therapies through early clinical trials, demonstrating superior efficacy or safety profiles compared to existing and emerging competitors. Strategic partnerships with large pharmaceutical companies are formed, validating its platform and pipeline, leading to a Series B/C valuation of $1.5B+.

Base (50%)+150%

The company makes steady progress in preclinical development and successfully moves one or more siRNA obesity candidates into Phase 1 clinical trials. While facing strong competition, Moonwalk secures its next funding round at a higher valuation, reaching approximately $750M, reflecting de-risking of its platform and initial clinical validation.

Bear (30%)-80%

Preclinical development faces significant setbacks, or the intense competition in the siRNA obesity space makes it difficult to differentiate. The company struggles to raise a subsequent funding round at a favorable valuation, potentially leading to a down round or acquisition at a significantly reduced valuation of $60M or less, severely impacting common stock value.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Investors hold $57M in liquidation preferences ahead of common shareholders, representing 19% of the estimated $300M post-money valuation.

Dilution Risk

high

As a preclinical biotech with high capital intensity, Moonwalk will require multiple significant funding rounds (Series B, C, etc.) to reach clinical trials and commercialization, leading to substantial future dilution for common shareholders.

Secondary Liquidity

none

Given the company's early (Series A) stage, there are currently no active secondary markets or tender offers for employee equity.

Other — 1 role

View all 1 open roles at Moonwalk →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Moonwalk's data — designed to show you've done your homework.

  • 1

    “Given the recent strategic shift to focus on siRNA obesity therapies, how does Moonwalk plan to differentiate its approach and pipeline from other well-funded RNAi players already in the clinic for obesity?”

  • 2

    “With the Series A funding providing approximately three years of runway, what are the key milestones and data readouts Moonwalk aims to achieve before initiating a Series B round, particularly concerning the progression of its obesity programs towards IND-enabling studies and clinical trials?”

  • 3

    “Considering the high capital intensity of drug discovery and development in this space, how is Moonwalk thinking about managing future dilution for employees, and what is the anticipated timeline for a potential liquidity event such as an IPO or acquisition?”

Community

Valuation Sentiment

Our model estimates -72% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.